-
公开(公告)号:US5952306A
公开(公告)日:1999-09-14
申请号:US783635
申请日:1997-01-14
Applicant: George D. Hartman , Mark E. Duggan , James J. Perkins , Cecilia A. Hunt , Amy E. Krause , John H. Hutchinson , Benny C. Askew , Karen M. Brashear , Nathan C. Ihle
Inventor: George D. Hartman , Mark E. Duggan , James J. Perkins , Cecilia A. Hunt , Amy E. Krause , John H. Hutchinson , Benny C. Askew , Karen M. Brashear , Nathan C. Ihle
IPC: C07D213/55 , C07D213/56 , C07D213/68 , C07D213/73 , C07D213/74 , C07D213/75 , C07D277/40 , C07D401/04 , C07D401/12 , C07D471/04 , C07K5/023 , A61K38/05 , A61K38/06
CPC classification number: C07D213/73 , C07D213/55 , C07D213/56 , C07D213/68 , C07D213/74 , C07D213/75 , C07D277/40 , C07D401/04 , C07D401/12 , C07D471/04
Abstract: Fibrinogen receptor antagonists having the formula ##STR1## for example ##STR2## which are useful for inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.
Abstract translation: 具有例如可用于抑制纤维蛋白原与血小板结合并抑制血小板聚集的配方的纤维蛋白原受体拮抗剂。
-
2.Guainidino, formamidino, amino and related compounds for inhibiting osteoclast-mediated bone resorption 失效
Title translation: 胍基,甲酰胺基,氨基和相关化合物,用于抑制破骨细胞介导的骨吸收公开(公告)号:US5929120A
公开(公告)日:1999-07-27
申请号:US15982
申请日:1998-01-30
Applicant: George D. Hartman , Mark E. Duggan , William F. Hoffman , Nathan C. Ihle
Inventor: George D. Hartman , Mark E. Duggan , William F. Hoffman , Nathan C. Ihle
IPC: C07D233/64 , A61K31/195 , A61K31/198 , A61K31/24 , A61K31/27 , A61K31/4045 , A61K31/415 , A61K31/4164 , A61K31/4168 , A61K31/4184 , A61K31/425 , A61K31/426 , A61K31/435 , A61K31/437 , A61K31/4375 , A61K31/44 , A61K31/47 , A61K31/472 , A61K31/505 , A61K31/513 , A61P19/10 , A61P43/00 , C07C229/34 , C07C257/14 , C07C271/20 , C07C271/22 , C07C279/04 , C07C279/22 , C07C311/19 , C07D209/12 , C07D213/73 , C07D217/22 , C07D233/26 , C07D233/48 , C07D233/54 , C07D233/88 , C07D235/30 , C07D239/06 , C07D239/14 , C07D239/22 , C07D239/26 , C07D277/20 , C07D277/40 , C07D277/42 , C07D471/04 , C07D521/00 , A61K31/155 , A61K31/19 , C07C257/10 , C07C307/02
CPC classification number: C07D213/73 , A61K31/198 , A61K31/27 , A61K31/4045 , A61K31/4164 , A61K31/4168 , A61K31/4184 , A61K31/425 , A61K31/426 , A61K31/437 , A61K31/4375 , A61K31/44 , A61K31/472 , A61K31/505 , A61K31/513 , C07C271/22 , C07C311/19 , C07D209/12 , C07D217/22 , C07D233/26 , C07D233/48 , C07D233/64 , C07D235/30 , C07D239/14 , C07D239/22 , C07D277/40 , C07D277/42 , C07D471/04
Abstract: Compounds of the following general structureX--Y--Z-Aryl-A--B, ##STR1## which inhibit osteoclast mediated bone resorption.
Abstract translation: 以下通用结构X-Y-Z-Aryl-A-B的化合物,其抑制破骨细胞介导的骨吸收。
-
公开(公告)号:US5919792A
公开(公告)日:1999-07-06
申请号:US959662
申请日:1997-10-28
Applicant: Mark E. Duggan , George D. Hartman , William F. Hoffman , Nathan C. Ihle
Inventor: Mark E. Duggan , George D. Hartman , William F. Hoffman , Nathan C. Ihle
IPC: C07D213/74 , C07D239/12 , C07D239/42 , C07D471/04 , A61K31/505 , A61K31/40 , A61K31/415 , A61K31/425 , A61K31/44 , C07D211/72 , C07D211/82 , C07D211/90 , C07D213/80 , C07D213/81 , C07D233/38 , C07D233/70 , C07D233/84 , C07D235/02 , C07D235/16 , C07D235/22 , C07D235/24 , C07D235/28 , C07D239/02 , C07D277/04 , C07D277/20 , C07D277/22 , C07D277/30 , C07D471/02
CPC classification number: C07D213/74 , C07D239/12 , C07D239/42 , C07D471/04
Abstract: This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.
-
公开(公告)号:US5852045A
公开(公告)日:1998-12-22
申请号:US729968
申请日:1996-10-15
Applicant: Ben C. Askew , George D. Hartman , Mark E. Duggan , Steven D. Young , John H. Hutchinson , John S. Wai , Melissa S. Egbertson , Laura M. Vassallo , Laura A. Libby , Amy E. Krause , Wasyl Halczenko , Nathan C. Ihle
Inventor: Ben C. Askew , George D. Hartman , Mark E. Duggan , Steven D. Young , John H. Hutchinson , John S. Wai , Melissa S. Egbertson , Laura M. Vassallo , Laura A. Libby , Amy E. Krause , Wasyl Halczenko , Nathan C. Ihle
IPC: C07D401/06 , C07D401/14 , C07D405/14 , C07D453/04 , C07D521/00 , C07K5/06 , A61K31/445 , A61K31/495
CPC classification number: C07D231/12 , C07D233/56 , C07D249/08 , C07D401/06 , C07D401/14 , C07D405/14 , C07D453/04 , C07K5/06026
Abstract: Fibrinogen receptor antagonists having the structure, for example, of ##STR1## for example ##STR2##
Abstract translation: 具有例如
结构的纤维蛋白原受体拮抗剂,例如 -
5.Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated bone resorption 失效
Title translation: 用于抑制破骨细胞介导的骨吸收的吡啶基和萘啶化合物公开(公告)号:US5741796A
公开(公告)日:1998-04-21
申请号:US714097
申请日:1996-09-26
Applicant: George D. Hartman , Mark E. Duggan , William F. Hoffman , Nathan C. Ihle
Inventor: George D. Hartman , Mark E. Duggan , William F. Hoffman , Nathan C. Ihle
IPC: C07D233/64 , A61K31/195 , A61K31/198 , A61K31/24 , A61K31/27 , A61K31/4045 , A61K31/415 , A61K31/4164 , A61K31/4168 , A61K31/4184 , A61K31/425 , A61K31/426 , A61K31/435 , A61K31/437 , A61K31/4375 , A61K31/44 , A61K31/47 , A61K31/472 , A61K31/505 , A61K31/513 , A61P19/10 , A61P43/00 , C07C229/34 , C07C257/14 , C07C271/20 , C07C271/22 , C07C279/04 , C07C279/22 , C07C311/19 , C07D209/12 , C07D213/73 , C07D217/22 , C07D233/26 , C07D233/48 , C07D233/54 , C07D233/88 , C07D235/30 , C07D239/06 , C07D239/14 , C07D239/22 , C07D239/26 , C07D277/20 , C07D277/40 , C07D277/42 , C07D471/04 , C07D521/00 , C07D213/02 , C07D487/04
CPC classification number: C07D213/73 , A61K31/198 , A61K31/27 , A61K31/4045 , A61K31/4164 , A61K31/4168 , A61K31/4184 , A61K31/425 , A61K31/426 , A61K31/437 , A61K31/4375 , A61K31/44 , A61K31/472 , A61K31/505 , A61K31/513 , C07C271/22 , C07C311/19 , C07D209/12 , C07D217/22 , C07D233/26 , C07D233/48 , C07D233/64 , C07D235/30 , C07D239/14 , C07D239/22 , C07D277/40 , C07D277/42 , C07D471/04
Abstract: Compounds of the following general structure X-Y-Z-Aryl-A-B, for example, ##STR1## which inhibit osteoclast mediated bone resorption. Specifically, the compounds are useful for treating mammals suffering from a bone condition caused or mediated by increased bone resorption, who are in need of such therapy. The compounds may be administered in oral dosage forms such as tablets, capsules, e.g. sustained release capsules, powders, granules, and suspensions.
Abstract translation: PCT No.PCT / US95 / 05938 Sec。 371日期1996年9月26日 102(e)1996年9月26日PCT PCT 1995年5月12日PCT公布。 公开号WO95 / 32710 日期1995年12月7日以下通用结构X-Y-Z-Aryl-A-B的化合物,例如抑制破骨细胞介导的骨吸收的
。 具体地说,这些化合物可用于治疗患有骨质状化的哺乳动物,所述骨骼状况由需要这种治疗的骨吸收增加引起或介导。 化合物可以口服剂型给药,例如片剂,胶囊剂例如 持续释放胶囊,粉末,颗粒和悬浮液。 -
6.Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents 失效
Title translation: 嘧啶甲酰胺衍生物及其作为抗炎剂的用途公开(公告)号:US07176310B1
公开(公告)日:2007-02-13
申请号:US10407870
申请日:2003-04-04
Applicant: Theodore A. Baughman , Jim P. Boyce , Ihab S. Darwish , J. Jeffry Howbert , Nathan C. Ihle , Randy W. Jackson , Scott C. Jeffrey , Dean Maeda , Kraig M. Yager
Inventor: Theodore A. Baughman , Jim P. Boyce , Ihab S. Darwish , J. Jeffry Howbert , Nathan C. Ihle , Randy W. Jackson , Scott C. Jeffrey , Dean Maeda , Kraig M. Yager
IPC: C07D239/00 , C07D239/70
CPC classification number: C07D239/47 , C07D401/04
Abstract: This invention is directed to compound of the following formula (I): wherein R1, R2, R3 and R4 are as described herein. These compounds and pharmaceutical compositions containing the compounds are useful in treating inflammatory disorders in mammals.
Abstract translation: 本发明涉及下式(I)的化合物:其中R 1,R 2,R 3和R 4 SUP>如本文所述。 这些化合物和含有这些化合物的药物组合物可用于治疗哺乳动物的炎性疾病。
-
公开(公告)号:US5854245A
公开(公告)日:1998-12-29
申请号:US883108
申请日:1997-06-26
Applicant: Mark E. Duggan , Melissa S. Egbertson , George D. Hartman , Steven D. Young , Nathan C. Ihle
Inventor: Mark E. Duggan , Melissa S. Egbertson , George D. Hartman , Steven D. Young , Nathan C. Ihle
IPC: C07D471/04 , C07D493/04 , A61K31/495 , A61K31/435 , C07D241/04 , C07D241/38
CPC classification number: C07D471/04 , C07D493/04
Abstract: Fibrinogen receptor antagonists having the structure X--Y--Z--A--B and pharmaceutically acceptable salts, wherein X is a 5, 6 or 7 membered aromatic or nonaromatic ring, and Y is a 5 or 6 membered aromatic ring, e.g., ##STR1##
Abstract translation: 具有结构X-Y-Z-A-Band药学上可接受的盐的纤维蛋白原受体拮抗剂,其中X是5,6或7元芳族或非芳族环,Y是5或6元芳族环,例如,
-
8.Method for incorporating radioactive phosphoric acid solutions in concrete 失效
Title translation: 将放射性磷酸溶液掺入混凝土中的方法公开(公告)号:US4442028A
公开(公告)日:1984-04-10
申请号:US396192
申请日:1982-07-08
Applicant: Gary A. Wolf , Jeffrey W. Smith , Nathan C. Ihle
Inventor: Gary A. Wolf , Jeffrey W. Smith , Nathan C. Ihle
Abstract: A method for incorporating radioactive phosphoric acid solutions in concrete is described wherein the phosphoric acid is reacted with Ca(OH).sub.2 to form a precipitate of hydroxyapatite and the hydroxyapatite is mixed with portland cement to form concrete.
Abstract translation: 描述了在混凝土中掺入放射性磷酸溶液的方法,其中磷酸与Ca(OH)2反应形成羟基磷灰石的沉淀物,羟基磷灰石与波特兰水泥混合形成混凝土。
-
-
-
-
-
-
-